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II  Guideline Application
=========================

Purpose and objectives
----------------------

This aim of this guideline is to create an interdisciplinary (including anaesthesiologists and intensive care physicians, obstetricians, midwives, puerperal care nursing staff) management and treatment algorithm for the management of peripartum haemorrhage (diagnosis, risk selection, therapy).

The guideline was compiled to improve the knowledge of all persons involved in the care of pregnant women and women in childbed who experience or have an increased risk of haemorrhage.

The aim was to improve the care of affected patients and reduce problems in the management of PPH.

Targeted areas of patient care
------------------------------

-   Outpatient care

-   Primary/specialised care

-   Inpatient care

Target user groups/target audience
----------------------------------

This guideline is aimed at the following groups of people:

-   gynaecologists/obstetricians in private practice (non-hospital based)

-   hospital-based gynaecologists/obstetricians

-   anaesthesiologists and intensive care physicians

-   haemostasis specialists and lab clinicians

-   interventional radiologists

-   midwives

-   nursing staff (surgery, anaesthesiology, intensive care unit, obstetrics/postpartum care)

Adoption of the guideline and period of validity
------------------------------------------------

The validity of this guideline was confirmed in September 2015 by the respective boards/representatives of the participating professional societies/working groups/organisations/associations, by the board of the DGGG and the DGGG Guideline Commission and by the SGGG and the OEGGG, which constitutes approval of the entire contents of the guideline. This guideline is valid from May 1, 2016 through to March 31, 2019. Because of the contents of this guideline, the above-mentioned period of validity is only an estimate. The guideline can be updated earlier if urgently required. Should the guideline continue to reflect the current level of scientific knowledge, then the guidelineʼs period of validity can be extended.

III  Methodology
================

Basic principles
----------------

The methodology used to compile this guideline is determined by the class assigned to the guideline. The AWMF Guidance Manual (version 1.0) has set out the respective rules and requirements. Guidelines are differentiated into lowest (S1), intermediate (S2) and highest (S3) class. The lowest class consists of a set of recommendations for action compiled by a non-representative group of experts. In 2004 the S2 class was divided into two subclasses: a systematic evidence-based (S2e) subclass and a structural consensus-based subclass (S2k). The highest S3 class combines both approaches.

This guideline is classified as: **S2k**

Grading of recommendations
--------------------------

The grading of evidence and the grading of recommendations was not envisaged for S2k class guidelines. Individual statements and recommendations are differentiated by syntax, not by symbols ( [Table 2](#TB5820122-2){ref-type="table"} ).

###### 

**Table 2**  Grading of recommendations.

  Description of grade of recommendation   Syntax
  ---------------------------------------- -------------------
  Strong recommendation, highly binding    must/must not
  Recommendation, moderately binding       should/should not
  Open recommendation, not binding         may/may not

The above classification of **recommendations** reflects the evaluated evidence and the clinical relevance of the studies on which the recommendations are based and various measures/factors which did not appear in the grading of evidence, such as the choice of patient population, intention-to-treat or per-protocol-outcome analyses, medical or ethical behaviour towards patients, country-specific application, etc.

Statements
----------

Expert statements included in this guideline which are not recommendations for action but simple statements of fact are referred to as **statements** . It is [not]{.ul} possible to provide a level of evidence for these statements.

Achieving consensus and level of consensus
------------------------------------------

During structured consensus-based decision-making (S2k/S3 level), the authorised representatives present at the respective session vote on draft Statements and Recommendations. Discussions during the session may lead to significant changes in the wording of Statements and Recommendations. At the end of the session, the extent of agreement (level of consensus) is determined based on the number of participants ( [Table 3](#TB5820122-3){ref-type="table"} ).

###### 

**Table 3**  Classification of extent of agreement in consensus decision-making.

  Symbol   Level of consensus   Extent of agreement in percent
  -------- -------------------- ------------------------------------
  +++      Strong consensus     \> 95% of participants agree
  ++       Consensus            \> 75 -- 95% of participants agree
  \+       Majority agreement   \> 50 -- 75% of participants agree
  --       No consensus         \< 50% of participants agree

Expert consensus
----------------

As the name implies, this refers to consensus decisions taken with regard to specific Recommendations/Statements without a previous systematic search of the literature (S2k) or when evidence is lacking (S2e/S3). The term "Expert Consensus" (EC) used here is synonymous with the terms "Good Clinical Practice" (GCP) and "Clinical Consensus Point" (CCP) used in other guidelines. The level of recommendation is graded as previously described in the Chapter Grading of recommendations but only semantically ("must"/"must not" or "should"/"should not" or "may"/"may not") and without using symbols.

IV  Guideline
=============

1  Introduction
---------------

The incidence of postpartum haemorrhage (PPH) is continually increasing [@R5820122-1] ,  [@R5820122-2] ,  [@R5820122-3] ,  [@R5820122-4] ,  [@R5820122-5] , mostly because of the increase in uterine atony and disorders of placental implantation and increased rates of surgical vaginal delivery and Caesarean sections and the consequent increase in primary blood loss and, in the case of Caesarean section, the increased PPH rates in subsequent pregnancies [@R5820122-2] ,  [@R5820122-6] ,  [@R5820122-7] ,  [@R5820122-8] ,  [@R5820122-9] ,  [@R5820122-10] ,  [@R5820122-11] .

In the western world, life-threatening postpartum haemorrhage occurs in approximately 2 of 1000 births and severe maternal morbidity occurs in around 3 of 1000 births [@R5820122-12] ,  [@R5820122-13] ,  [@R5820122-14] ,  [@R5820122-15] ,  [@R5820122-16] ,  [@R5820122-17] ,  [@R5820122-18] ,  [@R5820122-19] ,  [@R5820122-20] ,  [@R5820122-21] ,  [@R5820122-22] . PPH is the cause of approximately 30% of all maternal deaths in the Third World and 13% of maternal deaths in industrialised countries [@R5820122-21] .

The majority of maternal deaths from PPH could be avoided; major substandard care was present in 60 -- 80% of all cases [@R5820122-1] ,  [@R5820122-20] ,  [@R5820122-21] ,  [@R5820122-23] ,  [@R5820122-24] ,  [@R5820122-25] . What is especially alarming is that a visual estimation of blood loss during delivery results in the extent of bleeding being underestimated by 30 -- 50% [@R5820122-26] ,  [@R5820122-27] ,  [@R5820122-28] ,  [@R5820122-29] .

In Britain and America, the causes of PPH have been summarized as the "4 Ts". (Combinations of these causes are the rule.) ( [Table 4](#TB5820122-4){ref-type="table"} ).

###### 

**Table 4**  The 4 Ts: causes of PPH [@R5820122-6] ,  [@R5820122-16] ,  [@R5820122-30] ,  [@R5820122-31] ,  [@R5820122-32] .

  ------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Tone (uterine atony)      **Uterine distension** (multiparity, polyhydramnios, fetal macrosomia)\
                            Tocolytics\
                            Precipitate labour or prolonged labour\
                            (Prolonged) oxytocin augmentation\
                            Chorioamnionitis\
                            Uterine fibroids

  Tissue (placenta)         Retained placenta\
                            **Abnormally invasive placenta** (morbidly adherent placenta, placenta accreta/ increta/percreta)\
                            Placental remnants

  Trauma                    Vulvovaginal injury\
                            Cervical tear\
                            Episiotomy/perineal tear\
                            Uterine rupture\
                            Uterine inversion

  Thrombin (coagulopathy)   **Pregnancy-induced:**\
                            Thrombocytopenia (HELLP syndrome, disseminated intravascular coagulation \[DIC\]) (e.g. in pre-eclampsia, intrauterine fetal death \[IUFD\], placental abruption, amniotic fluid embolism)\
                            **Other:**\
                            von Willebrand disease, plasmatic coagulopathies, thrombopathy, coagulation factor deficiencies (loss, consumption, dilution)
  ------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The main risk management problems in the management of PPH are [@R5820122-1] ,  [@R5820122-24] ,  [@R5820122-33] ,  [@R5820122-34] :

-   Delayed diagnosis and/or therapy due to underestimation of the actual amount of blood lost

-   Delayed provision of blood or coagulation products

-   Lack of or failure to follow simple instructions

-   Lack of adequate training or advanced training

-   Poor communication within the interdisciplinary team

-   Deficits in the organisational structure

-   Delay in initiating treatment standards

2  Definitions
--------------

  Consensus-based Recommendation 2.E1
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  The following **definition of PPH** is proposed (for German-speaking areas): Blood loss of ≥ 500 ml following vaginal deliveryBlood loss of ≥ 1000 ml following Caesarean section

3  Risk Stratification and Prevention
-------------------------------------

A complete and detailed patient history, ultrasound examination during antenatal appointments, assessment of the patientʼs risk of bleeding, presentation to the maternity hospital, and preparations for increased blood loss could reduce patientsʼ risk of PPH [@R5820122-35] .

  Consensus-based Recommendation 3.E2
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Location and structure of the placenta must be documented during ultrasound examination in the 2nd trimester. If necessary, patients with low-lying placenta should undergo an additional ultrasound scan to screen for vasa praevia and the findings should be documented [@R5820122-36] .

  Consensus-based Recommendation 3.E3
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------
  An implantation disorder should be considered in women with a high-risk history (previous operations) or findings (placenta praevia) which indicate high risk.

### 3.1  Risk stratification and risk factors which facilitate peripartum/postpartum haemorrhage ( [Table 5](#TB5820122-5){ref-type="table"} )

###### 

**Table 5**  Risk factors for PPH [@R5820122-16] ,  [@R5820122-23] ,  [@R5820122-37] ,  [@R5820122-38] ,  [@R5820122-39] .

                                        **Odds ratio or range**   
  ------------------------------------- ------------------------- --------------
  Blood loss                            \> 500 ml                 \> 1000 ml
  Sociodemographic risk factors                                   
  obesity (BMI \> 35)                   1.6                       
  maternal age (≥ 30 years)             1.3 -- 1.4                1.5
  Obstetric risk factors                                          
  placenta praevia                      4 -- 13.1                 15.9
  premature placental separation        2.9 -- 12.6               2.6
  retained placenta                     4.1 -- 7.8                11.7 -- 16.0
  prolonged expulsion of the placenta   7.6                       
  pre-eclampsia                         5.0                       
  grand multiparity                     2.3 -- 4.5                2.6
  s/p PPH                               3.0 -- 3.6                
  fetal macrosomia                      1.9 -- 2.4                
  HELLP syndrome                        1.9                       
  Polyhydramnios                        1.9                       
  (prolonged) oxytocin augmentation     1.8                       
  labour induction                      1.3 -- 2                  2.1 -- 2.4
  protracted labour                     1.1 -- 2                  
  Surgical risk factors                                           
  emergency Caesarean section           3.6                       
  elective Caesarean section            2.5                       
  operative vaginal delivery            1.8 -- 1.9                
  episiotomy                            1.7 -- 2.21               2.07
  perineal tear                         1.7                       2.5
  Other risk factors                                              
  antepartum haemorrhage                3.8                       
  von Willebrand disease                3.3                       
  anaemia (\< 9 g/dl)                   2.2                       
  fever during delivery                 2                         

Other risk factors include precipitous birth, high maternal parity, fibroids and uterine malformations [@R5820122-39] .

**[Caution:]{.ul}** The majority of patients who develop PPH do not have identifiable risk factors [@R5820122-39] .

### 3.2  Sonographic risk stratification (placentation disorders)

  Consensus-based Recommendation 3.E4
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patients with suspected abnormally invasive placenta must present early to a suitable maternity hospital where they must be treated by a multidisciplinary team ("by the best team at an optimal point in time") [@R5820122-20] ,  [@R5820122-40] .

The diagnostic value of MRI has not yet been convincingly demonstrated in these cases [@R5820122-41] ,  [@R5820122-42] , but MRI examination could provide additional information when findings are ambiguous [@R5820122-42] ,  [@R5820122-43] .

### 3.3  Prevention

#### 3.3.1  Active management of third stage of labour

##### 3.3.1.1  Active management after vaginal delivery

  Consensus-based Recommendation 3.E5
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  After the infant has been born and commenced breathing, oxytocin (Syntocinon ^®^ 3 -- 5 IU slow IV infusion) must be administered for PPH prevention [@R5820122-44] .

  Consensus-based Recommendation 3.E6
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------
  Immediate clamping of the umbilical cord at birth and controlled cord traction have no impact on reducing postpartum haemorrhage and should not be carried out.

##### 3.3.1.2  Prevention of PPH during Caesarean section

  Consensus-based Recommendation 3.E7
  --------------------------------------------------------------
  PPH prophylaxis must be administered as in vaginal delivery.

Prophylaxis can consist of administering either oxytocin (Syntocinon ^®^ 3 -- 5 IU by short infusion \[or slow IV infusion\]) or carbetocin (Pabal ^®^ 100 µg) by short infusion or slow IV infusion.

#### 3.3.2  If risk factors are present

  Consensus-based Recommendation 3.E8
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  If risk factors are present, the following measures must be taken:Adequate venous access for every woman in labour, adequate intravenous access in case of complications of bleedingUterotonics must be available (oxytocin, e.g. Syntocinon ^®^ ), prostaglandins (e.g. sulprostone: Nalador ^®^ ), misoprostol (Cytotec ^®^ , off-label use)Check logistics:Check availability of emergency laboratory tests (complete blood count, blood gas analysis \[BGA\], aPTT, prothrombin time \[PT\] or INR, antithrombin \[AT\], fibrinogen, possibly thromboelastography or thromboelastometry \[ROTEM\])Obstetrician and anaesthesiologist must be on site, experienced obstetrician and experienced anaesthesiologist on callCheck availability of blood products: cross-matching, ordering of packed red blood cells, fresh frozen plasma and plateletsCheck availability of haemostatic agents (tranexamic acid \[Cyclokapron ^®^ \], fibrinogen \[Haemocomplettan ^®^ \], factor XIII \[Fibrogammin ^®^ \], recombinant activated factor VII a \[rFVIIa, NovoSeven ^®^ , off-label use\]).

4  Management of PPH
--------------------

  Consensus-based Statement 4.S1
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Alongside general interventions (such as stabilising the patientʼs haemodynamic status), causal treatment of PPH includes medical therapy and/or surgical procedures that must be performed quickly, in a coordianted and often simultaneous manner [@R5820122-45] ,  [@R5820122-46] ,  [@R5820122-47] .

### 4.1  Procedures

-   Measure blood loss! (Caution: blood loss in bandages, etc.)

-   Rapid diagnosis of the cause of bleeding (4 Tʼs):

    -   Estimation of uterine tone

    -   Check whether placenta is complete (ultrasound, manual or instrumental examination)

    -   Exclude vulvovaginal trauma by speculum examination

    -   Administer uterotonics (in case of atony) and tranexamic acid to treat critical blood loss

    -   Uterine compression

-   Call in anaesthesiologist (multidisciplinary team) at an early stage

-   Drug therapy and/or surgical procedures, depending on the cause of bleeding

-   Control vital signs, consider timely invasive monitoring

-   Initial volume substitution to maintain normovolaemia: cristalloids, in exceptional cases (e.g. acute haemorrhage and haemodynamic instability) colloidal solutions [@R5820122-48]

-   Cross-matching of blood, emergency laboratory tests (incl. full blood count, coagulation)

-   Order packed red blood cells and fresh frozen plasma, provide blood products if required (delivery room, operating theatre)

-   Coagulation factors, especially fibrinogen

-   Other haemostatic agents (e.g. desmopressin), factor XIII or rFVIIa if necessary

-   Intensive monitoring of patient during hospital stay, consider invasive monitoring

-   Timely surgical intervention when conservative measures fail (see below for appropriate procedures)

#### Measuring blood loss

One of the cardinal problems which occur not only when defining but primarily when diagnosing and treating PPH is that the extent of postpartum blood loss is rarely measured and **is known to be underestimated by 30 -- 50% if assessment is done on a purely visual basis** [@R5820122-35] ,  [@R5820122-49] .

  Consensus-based Recommendation 4.E9
  -----------------------------------------------------------------------------------------------------
  Collecting all blood-soaked pads, bedding, linens and significant coagulum is strongly recommended.

5  General (Emergency) Measures and Diagnosis to Determine Causes of PPH
------------------------------------------------------------------------

### 5.1  Atony

-   [Diagnosis:]{.ul} increased fundal height; soft slack uterus; usually intermittent heavy bleeding.

-   Void the bladder!

-   Mechanical procedures: uterine massage (endogenous prostaglandin formation), bimanual uterine compression (e.g. Hamiltonʼs manoeuvre)

-   Exclude vulvovaginal trauma (by speculum examination and abdominal US if necessary)

-   Exclude retained placenta (examine the placenta to ensure it is complete, sonography)

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Consensus-based Recommendation 5.E10
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Therapy:**\
  After vaginal delivery\
  uterotonics, tranexamic acid if requiredcareful curettage in the delivery room or operating theatre if retained placenta is suspecteduterine tamponade if requiredother surgical proceduresconsider embolisationAfter caesarean sectionuterotonics, tranexamic acid if requiredsurgical procedures

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

### 5.2  Implantation disorders

The management of abnormally invasive placenta depends on the time of diagnosis and type of delivery.

#### Approach for antenatal diagnosis

If an advanced implantation disorder (placenta increta, percreta) is diagnosed in the antenatal period, delivery must always be by Caesarean section.

-   Extensive findings: Caesarean section with hysterectomy; alternatively, consider expectant management (e.g. delayed delivery of placenta)

-   Focal findings: partial resection of the uterine wall

-   If necessary carry out interventional radiology with prophylactic occlusion of the internal iliac arteries [@R5820122-50] ,  [@R5820122-51]

#### Approach for intrapartum diagnosis

-   Vaginal delivery:

    -   If the placenta fails to separate and bleeding is present: carry out manual separation of the placenta followed by curettage with intraoperative ultrasound monitoring, if required [@R5820122-52]

    -   If severe bleeding from the placental bed persists: carry out surgical therapy, alternatively embolisation of the uterine arteries

-   Caesarean section:

    -   Do not manipulate the placenta or attempt to separate it manually

    -   Perform Caesarean section with hysterectomy or alternatively consider expectant management (e.g. delayed delivery of placenta)

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Consensus-based Recommendation 5.E11
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Therapy:**\
  After vaginal delivery\
  uterotonics, tranexamic acid if requiredif necessary, manual separation of the placenta followed by curettageif necessary, uterine tamponade as a bridging procedurelaparotomy and other surgical measurespossibly embolisationAfter Caesarean sectionuterotonics, tranexamic acid if requiredsurgical measuresconsider embolisation

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

### 5.3  Uterine inversion

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Consensus-based Recommendation 5.E12
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Therapy:**\
  The goal is the reposition of the uterus and treatment of the symptoms of haemorrhagic shock. The following procedures must be carried out immediately after making the diagnosis in the order stated below:Stop administration of any uterotonic drugCall in experienced obstetrician and anaesthesiologistEnsure adequate intravenous access, volume substitutionMake no attempt to remove the placenta (higher blood loss); the placenta must, where possible (placenta accreta), only be removed after repositioning [@R5820122-53] ,  [@R5820122-54]Attempt to reposition the fundus (Johnsonʼs manoeuvre)If attempts at repositioning are unsuccessful, administer uterine relaxants (e.g. nitroglycerin 50 µg IV, betamimetics) and repeat the attempt to reposition the uterus with Johnsonʼs manoeuvreIf repositioning attempts continue to be unsuccessful → perform laparotomy and Huntingtonʼs procedure, simultaneously with Johnsonʼs manoeuvre if necessary; if attempts are still unsuccessful, perform the Haultain procedureAdminister uterotonics (e.g. oxytocin) after successful repositioningProvide antibiotic protection (e.g. cephalosporin or clindamycin)

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

6  Medication and Surgical Measures to Treat PPH
------------------------------------------------

### 6.1  Uterotonics

#### 6.1.1  Oxytocin (Syntocinon ^®^ ) IV (IM if necessary)

  Consensus-based Recommendation 6.E13
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  A maximum of 6 IU undiluted oxytocin can be administered slowly and intravenously:3 -- 5 IU (1 vial) in 10 ml NaCl 0.9% as a single (slow intravenous!) bolusIf necessary, this can be followed by 10 -- 40 IU oxytocin in 500 -- 1000 ml saline as a continuous infusion (dose depends on the clinical situation, particularly the impact on uterine tone) [@R5820122-16] ,  [@R5820122-55] .

The onset of action after IV administration (half-life of 4 -- 10 min) is less than one minute or 3 -- 5 minutes following intramuscular administration (maximum 10 IU).

#### 6.1.2  Carbetocin (Pabal ^®^ )

The use of carbetocin to treat PPH is currently not yet been sufficiently investigated. The use of carbetocin to treat PPH has been reported in individual cases.

#### 6.1.3  Methylergometrine (Methergin ^®^ )

  Consensus-based Recommendation 6.E14
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Given the range of serious side effects and the fact that better alternatives are available, the utmost caution is advised when administering methylergometrine to manage postpartum haemorrhage.

  Consensus-based Recommendation 6.E15
  -----------------------------------------------------------------------
  Methylergometrine should not be administered as an intravenous bolus.

#### 6.1.4  Prostaglandins

  Consensus-based Recommendation 6.E16
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------
  If first-line uterotonics are not effective and patients do not respond to first-line uterotonics, prostaglandins must be administered immediately [@R5820122-56] .

  Consensus-based Recommendation 6.E17
  ----------------------------------------------------------------------------------------
  Oxytocin receptor agonists and prostaglandins must not be administered simultaneously.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Consensus-based Statement 6.S2
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Note:**\
  Postpartum uterine atony and uterine haemorrhage are life-threatening pathologies and an urgent indication for the administration of prostaglandin derivatives if no other alternatives are available or oxytocin is not effective, until patients can receive obstetric/gynaecological treatment. In this situation the side effects and contraindications must be carefully considered (benefits and drawbacks weighed up). Close haemodynamic monitoring is necessary when prostaglandin derivatives are administered.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

##### 6.1.4.1  Sulprostone (Nalador ^®^ )

**Dosage:**

-   1 vial = 500 µg in 500 ml solution administered via an infusion pump

-   Initial dose: 100 ml/h, up to a maximum of 500 ml/h if required

-   Maintenance dose: 100 ml/h

-   Maximum dose 1000 µg/10 hours (2 vials)

-   Maximum daily dose 1500 µg (3 vials)

##### 6.1.4.2  Misoprostol (Cytotec ^®^ )

**Dosage:** 800 -- 1000 µg misoprostol administered rectally or 600 µg administered orally [@R5820122-57]  --  [@R5820122-60] .

A Cochrane meta-analysis showed that oxytocin infusion was more effective as a first-line therapy than the administration of misoprostol and additionally had fewer side effects. When used after prophylactic uterotonics, misoprostol and oxytocin were equally effective [@R5820122-61] .

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Consensus-based Statement 6.S3
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Note:**\
  Because of its delayed onset of action and the availability of better and approved alternatives, misoprostol is not suitable to treat persistent PPH.\
  The use of misoprostol to treat moderately persistent PPH after the administration of oxytocin may be considered (off-label use!). However, the current data is still insufficient to make a final recommendation.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Consensus-based Statement 6.S4
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Note:**\
  Postpartum uterine atony and uterine haemorrhage are life-threatening pathologies and the administration of misoprostol is urgently indicated if no other alternatives are available, until patients can receive obstetric/ gynaecological treatment. In this context the side effects and contraindications must be carefully considered (benefits and drawbacks weighed up). Close haemodynamic monitoring is essential when misoprostol is administered.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

##### 6.1.4.3  Intrauterine application of prostaglandins

  Consensus-based Statement 6.S5
  --------------------------------------------------------------------------------------------------------------------------------------------------
  The intramyometrial application of sulprostone (e.g. to the uterine fundus in cases with caesarean section) is contra-indicated [@R5820122-56] .

7  Uterine Tamponade
--------------------

The objective of uterine cavity tamponade is twofold: to treat PPH (i.e., to achieve definitive haemostasis) and as a "bridging" measure (i.e., to achieve temporary haemostasis and haemodynamic stabilisation and allow other measures \[surgical or interventional radiology\] to be put in place) [@R5820122-62] ,  [@R5820122-63] ,  [@R5820122-64] . In addition to other second-line treatment strategies, uterine tamponade can significantly reduce the rate of emergency hysterectomies [@R5820122-65] ,  [@R5820122-66] .

In addition to tamponade strips, there are a number of different balloon tamponade systems available for uterine tamponade; their efficacy has been described in various publications and their use has the advantage of allowing the early detection of persistent bleeding [@R5820122-64] ,  [@R5820122-67] ,  [@R5820122-68] ,  [@R5820122-69] ,  [@R5820122-70] ,  [@R5820122-71] ,  [@R5820122-72] ,  [@R5820122-73] .

  Consensus-based Recommendation 7.E18
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Parallel administration of uterotonicsVaginal examination/ultrasound (to exclude trauma, retained placenta, clot evacuation)Bladder catheterUse a liquid (0.9% saline, body temperature if possible) to fill the balloon tamponade -- NOT airAdditional vaginal tamponadeIntensive monitoring, antibiotic prophylaxisCan be left in utero for up to 24 hours

There has been a recent report on the use of a special gauze (Celox ^®^ ) coated with a haemostatic agent (chitosan), originally developed for emergency treatment and military combat medicine, to successfully manage PPH [@R5820122-74] .

  Consensus-based Recommendation 7.E19
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Uterine tamponade -- in whatever form -- does not preclude other necessary therapeutic options, such as compression sutures [@R5820122-64] ,  [@R5820122-75] ; the use of compression sutures is strongly recommended, particularly to treat atony [@R5820122-75] ,  [@R5820122-76] ,  [@R5820122-77] ,  [@R5820122-78] .

8  Surgical Measures (Compression, Devascularisation, Hysterectomy) and Embolisation
------------------------------------------------------------------------------------

### 8.1  Bridging procedures

  Consensus-based Recommendation 8.E20
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  In the event of the lethal triad consisting of persistent haemorrhage, haemorrhagic shock und coagulopathy, the following three-stage approach is recommended [@R5820122-62] : Early surgical haemostasis carried out by the attending surgical obstetrician using a Pfannenstiel incision or median laparotomy, eventeration of the uterus with cranial traction and uterine compression, and atraumatic clamping of the uterine arteries to minimise perfusion. Placement of uterine compression sutures and application of a uterine tamponade.Parallel correction of hypovolaemia, temperature, disturbed acid-base balance and coagulopathy by the anaesthesiologist; if possible, surgery should then be paused until stabilisation.Definitive (surgical) treatment of the now haemodynamically stable patient by a surgeon with the appropriate surgical expertise. If the necessary infrastructure is available, option to perform interventional radiological embolisation of afferent uterine arteries [@R5820122-79] ,  [@R5820122-80] . The benefit of this approach is that it can preserve fertility, as has been described for large case series [@R5820122-81] ,  [@R5820122-82] ,  [@R5820122-83] ,  [@R5820122-84] .

### 8.2  Uterine compression sutures

The aim of these sutures is to compress the uterus, reduce the placental adhesion area and tamponade the bleeding site. This approach is indicated for uterine bleeding after vaginal delivery or following Caesarean section. At present it is not possible to say anything about the optimal efficacy of specific types of sutures. All of the employed methods had high success rates in terms of preventing hysterectomy which would otherwise have been necessary. The choice of the appropriate suture method depends on the indication (atony, bleeding from the placental bed, diffuse bleeding) [@R5820122-85] .

  Consensus-based Recommendation 8.E21
  --------------------------------------------------------------------------------------------------------------------
  Suitable suture materials (large needles, long suture threads) must be kept in readiness in the operating theatre.

### 8.3  Vascular ligatures

In addition to simple ligature of the uterine artery [@R5820122-86] stepwise uterine devascularisation can also be used for haemostasis. The technique consists of 5 consecutive steps to ligate the ascending and descending branches of the uterine arteries and the ovarian arterial collaterals [@R5820122-87] ,  [@R5820122-88] .

  Consensus-based Recommendation 8.E22
  ----------------------------------------------------------------------------------------------------------------------------------------------------
  Ligature of the internal iliac artery must only be carried out as a last resort and only by a surgeon with extensive experience of pelvic surgery.

### 8.4  Postpartum hysterectomy

  Consensus-based Recommendation 8.E23
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Conservative measures to preserve the uterus are only useful if the patient is haemodynamically stable and does not have life-threatening bleeding [@R5820122-89] ,  [@R5820122-90] . The decision that hysterectomy is indicated must not be delayed or left too late.

  Consensus-based Recommendation 8.E24
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Supracervical hysterectomy is the procedure of choice for atony, as the operating time is significantly shorter and the operation does not lead to unintended vaginal shortening. Total hysterectomy should be considered for placental implantation disorders of the lower uterine segment; visualisation of the ureters during this procedure is recommended.

#### Relative contraindications for uterus-preserving measures are:

-   Extensive abnormally invasive placenta (placenta increta/percreta) where the placental implantation bed is open, bleeding from the placental implantation bed is resistant to treatment or the implantation bed covers large areas of the uterine wall.

-   Non-reconstructable uterine injury

-   Septic uterus

  Consensus-based Recommendation 8.E25
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  During the bridging time to definitive treatment, (bimanual) compression of the aorta for up to 20 minutes may be carried out to avoid unnecessary blood loss [@R5820122-91] ,  [@R5820122-92] . If it is clear that the haemorrhage cannot be controlled by hysterectomy or is continuing even though hysterectomy has been carried out, the lesser pelvis and abdomen should be packed with sufficient moistened abdominal cloths.

### 8.5  Arterial catheter embolisation

  Consensus-based Recommendation 8.E26
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Every obstetric department should ascertain whether arterial catheter embolisation can be performed in their facility and the time it takes for this method to be available and then create the organisational structure which will determine at what point the patient should be transferred to the interventional radiology department. The precondition for transfer is that the patient is haemodynamically stable and does not have massive bleeding.

  Consensus-based Recommendation 8.E27
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  If catheter embolisation is available on site, the radiologist should be notified early (e.g. when an attempt at haemostasis using uterine compression sutures is unsuccessful). Because of the range of side effects, medical and surgical treatment options should be largely exhausted. The time of transfer to the radiology department is also determined by how important it is to preserve the uterus.

  Consensus-based Recommendation 8.E28
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Before the patient is transferred, intra-abdominal packing should be considered as a bridging procedure if the patient has just undergone a hysterectomy procedure to prevent a critical loss of blood during transportation and contain the bleeding during the sometimes protracted intervention.

  Consensus-based Recommendation 8.E29
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  If the intervention can be planned ahead (e.g., placenta increta/percreta), endovascular catheters can already be placed preoperatively into the internal iliac artery on both sides.

Catheter embolisation may be used as a last resort to treat persistent diffuse bleeding in the lesser pelvis after postpartum hysterectomy [@R5820122-93] .

9  Haemostasis and Coagulation Management -- Intensive Medical Procedures
-------------------------------------------------------------------------

### 9.1  Background

Understanding and recognising the most probable pathophysiology of the bleeding is important, as this will offer pointers for different therapeutic approaches. The problem associated with haemostatic management is the difficulty in differentiating between increased bleeding caused by a major injury and protracted bleeding where the composition of blood has changed (i.e., the normal capacity of the system to compensate for smaller injuries has been reversed; this equates to an impairment of the coagulation system = coagulopathy). It is therefore necessary to distinguish between:

-   trauma-induced coagulopathy with shock and massive tissue trauma

-   initial "traumatic" haemorrhage caused by tissue trauma, and

-   initial coagulopathic bleeding.

Impaired coagulation (= coagulopathy) is often an early pathology of PPH which can occur before dilutional coagulopathy occurs [@R5820122-39] ,  [@R5820122-94] .

  Consensus-based Recommendation 9.E30
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  The length of time needed to obtain diagnostic findings means that it is not possible to await the results of diagnostic procedures which differentiate between different coagulopathies (e.g. congenital vs. acquired) before making treatment decisions. As a rule (if the patientʼs medical history does not indicate any congenital coagulopathy), it should be assumed that patients with peripartum or postpartum haemorrhage have an acquired coagulopathy, unless a surgical cause of haemorrhage can be clearly identified.

It is also important to take account of the fact that, because of the associated dilution effect and the use of coagulation factors, every primary mechanical bleeding treated with volume replacement and fresh frozen plasma (FFP) will become coagulopathic if volume substitution and FFP administration is continued over a lengthy period [@R5820122-95]  --  [@R5820122-97] .

  Consensus-based Statement 9.S6
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  It is therefore essential that all hospitals with obstetric departments develop a treatment algorithm for peri-/postpartum haemorrhage which is adapted to the specific conditions in the respective hospital [@R5820122-46] ,  [@R5820122-98] ,  [@R5820122-99] ,  [@R5820122-100] ,  [@R5820122-101] . The aim must be to identify haemorrhaging patients early on and describe the appropriate interdisciplinary surgical, interventional and haemostatic treatment to manage the bleeding. This algorithm should define the approach for the treatment process based on the clinical situation and take account of all available treatment options (pharmacological therapies, interventional procedures, surgical interventions).

### 9.2  Options to treat peri-/postpartum coagulopathic haemorrhage

  Consensus-based Statement 9.S7
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  During active bleeding, any iatrogenic aggravation of the tendency to bleed (e.g. by administering artificial colloids for volume replacement which has a strong dilution-related coagulopathic effect, or attempt to achieve high-normal blood pressure) should be avoided, where possible.

  Consensus-based Statement 9.S8
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Blood component therapy is currently the standard therapy for haemostasis, either using labile (cellular components, FFP) or stable (lyophilised factor concentrates) blood products, and should be administered early to prevent dilutional coagulopathy occurring in addition to the already existing loss of blood.

Based on the current state of knowledge, f **ibrinogen** plays a key role. In patients with a history of peri-/postpartum haemorrhage and patients with peripartum bleeding, plasma fibrinogen concentrations should be determined (irrespective of treatment), as concentrations \< 2 g/l could help identify those patients at increased risk of severe PPH [@R5820122-39] ,  [@R5820122-46] .

  Consensus-based Recommendation 9.E31
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  In any case, potentially increased fibrinolytic activity should be treated by the administration of **tranexamic acid** (an antifibrinolytic) before the substitution of fibrinogen (factor concentrate or FFP) is considered [@R5820122-39] .

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Consensus-based Statement 9.S9
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  The beneficial effects (lower loss of blood, reduced blood transfusion, increased Hb, lower number of invasive procedures) of administering tranexamic acid to treat PPH have since been shown in randomised, controlled studies of around 2000 patients [@R5820122-102] ,  [@R5820122-103] ,  [@R5820122-104] ,  [@R5820122-105] ,  [@R5820122-106] ,  [@R5820122-107] ,  [@R5820122-108] ,  [@R5820122-109] ,  [@R5820122-110] .\
  In 2013 the ESA issued a strong recommendation based on moderate evidence for the administration of tranexamic acid to treat obstetric bleeding to reduce blood loss, bleeding duration and the number of transfusions [@R5820122-46] .\
  There are no reliable data on the use of **DDAVP** (Minirin ^®^ ) in obstetrics which would permit an evidence-based recommendation [@R5820122-111] , although there have been repeated reports of observational studies with positive outcomes [@R5820122-112] . According to the ESA, DDAVP may be useful to treat platelet function disorders resulting from acquired von Willebrand syndrome (from drugs, acidosis, hypothermia) [@R5820122-46] .

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Consensus-based Recommendation 9.E32
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Although the data is controversial and prospective randomised studies are lacking, one or two attempts at treatment with rFVIIa at a dose of 90 µg/kg BW can be undertaken as a last resort in carefully selected cases if\
  the patient has previously received adequate and appropriate treatment with other blood products,the other methods used for haemostasis were not sufficiently effective, andthe patient still wants to have other children before undergoing a hysterectomy [@R5820122-39] ,  [@R5820122-113] ,  [@R5820122-114] ,  [@R5820122-115] ,  [@R5820122-116] . Because of the risk of thromboembolism, recombinant FVIIa (NovoSeven ^®^ ) should only be given as a last resort [@R5820122-117] . Plasmatic factor concentrations and platelet numbers should be optimised before rFVIIa is administered [@R5820122-46] .

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

  Consensus-based Statement 9.S10
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  In summary, the conclusions to be drawn from the currently available data on haemostatic management recommendan escalating concept (i.e., a successive step-by-step range of treatment options) adapted to the respective conditions in each hospital [@R5820122-46] ,  [@R5820122-99] ,  [@R5820122-100] ,early administration of tranexamic acid, preferably immediately after making the diagnosis,stabilisation of physiological preconditions for coagulation (i.e. pH, temperature, calcium level) [@R5820122-46] ,  [@R5820122-95] ,if bleeding persists, viscoelastic test or conventional diagnostic tests to diagnose the cause of bleeding,if bleeding persists and substitution is required (if need be, in parallel to other mechanical forms of treatment), early replacement of coagulation factors with factor concentrates and/or FFP (fibrinogen should be considered if dilutional coagulopathy is present, otherwise PCC and F XIII may be used),if necessary (i.e. when other approaches are not effective), optimisation of platelet numbers (target \> 100,000/µl for patients with active bleeding requiring transfusion) [@R5820122-46] .

  Consensus-based Recommendation 9.E33
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  After the underlying cause of bleeding has been treated, thromboprophylaxis must be administered within 24 hours [@R5820122-39] . Because of the reduced antithrombin activity (absolute activity may even be less than 0.5 kIU/l) in the majority of women with PPH, an increased risk of thromboembolism is expected **after the bleeding has stopped** [@R5820122-118] . After the administration of individual coagulation factor concentrates or complex preparations (e.g. PCC), antithrombin activity can be determined on the intensive care unit and substituted if necessary [@R5820122-119] . The target value is ≥ 80% or ≥ 0.8 kIU/l [@R5820122-119] ,  [@R5820122-120] ,  [@R5820122-121] .

### 9.3  Anaesthesia-related aspects of managing PPH

  Consensus-based Recommendation 9.E34
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Maintain or achieve haemodynamic stability and normovolaemia: **myocardiac ischaemia** with reduced contractility is often present when Hb values ≤ 6 g/dl (3.726 mmol/l) with or without haemodynamic abnormality (RR ~sys~  \< 90 mmHg and/or RR ~dia~  \< 50 mmHg and/or HR ≥ 115/min) [@R5820122-122] ,  [@R5820122-123] .**Timely call for expert assistance** is recommended for uncontrolled blood loss of more than 500 ml following vaginal delivery or more than 1000 ml following Caesarean section and is essential if blood loss is more than 1500 ml [@R5820122-29] ,  [@R5820122-89] ,  [@R5820122-95] ,  [@R5820122-124] .For patients receiving **regional anaesthesia** (spinal anaesthesia, epidural anaesthesia): if blood loss is ≥ 1500 -- 2000 ml and there are signs of persistent bleeding: **secure the airway and ensure sufficient oxygen supply** ; if necessary, perform early intubation after consultation with the surgeon [@R5820122-125] . If there is a loss of protective reflexes, endotracheal intubation to secure the airway and ensure sufficient oxygenation must take priority.Place **wide-diameter** access points (2× ≥ 16 G) followed by arterial blood pressure measurement, if necessary even before intubation. A wide-diameter central access (≥ 9 Fr) is recommended [@R5820122-125] ,  [@R5820122-126] ,  [@R5820122-127] ,  [@R5820122-128] .**Cell saver** blood (official recommendations of CMACE, NICE, OAA/AAGBI, ESA): use of mechanical autotransfusion in patients undergoing elective Caesarean section (e.g. in cases with placenta increta/percreta) can reduce the administration of allogenic blood postoperatively and the duration of hospital stay [@R5820122-129] ,  [@R5820122-130] . In the emergency setting of PPH the following **[caveats]{.ul}** must be taken into consideration: should only be used, after amniotic fluid removal and delivery of the neonate.Cell-saver blood does not contain clotting factors or platelets. Coagulation factors should be substituted to prevent coagulopathy when administering high transfusion volumes [@R5820122-131] .Cases of hypotension have been reported following the re-transfusion of cell-saver blood with a leukocyte depletion filter [@R5820122-132] .**Target values in haemodynamic therapy** for "healthy" pregnant women and strong bleeding:**After cord clamping, hypotensive resuscitation** until surgical haemostasis is achieved with **restrictive fluid therapy** [@R5820122-133] ,  [@R5820122-134] ."Normal recapillarisation time" or "palpable radial pulse" are the target values for volume replacement therapy [@R5820122-135] ,  [@R5820122-136]**Goal:** MAP \> 65 mmHg or lower [@R5820122-137] or RR ~sys~  \~ 90 mmHg [@R5820122-138] .**Target Hb:** indication for blood transfusion until surgical haemostasis: **7 g/dl** (4.347 mmol/l); after surgical haemostasis and successful treatment of the underlying pathology: **7 -- 9 g/dl** (4.347 -- 5.589 mmol/l) [@R5820122-23] ,  [@R5820122-134] ,  [@R5820122-138] . Note: ensure sufficient additional iron supplementation on the ward postoperatively.**Pharmacological thromboprophylaxis** within 24 hours after the pathology causing the bleeding has been treated [@R5820122-134] .

###### 

Escalating regimen of haemostatic therapeutic options to treat PPH (based on recommendations of the S3-guideline 012/019 "Polytrauma/Schwerverletztenbehandlung" \[Multitrauma/Treatment of Severely Injured Persons\], DGAI recommendations on treating severe bleeding and ESA recommendations on treating perioperative haemorrhage) [@R5820122-100] ,  [@R5820122-136] .

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------
  1\.                                                                                                                                                                                                                                      Stabilise general conditions (prophylaxis and therapy!)                                                                        Core temperature ≥ 34 °C (preferably normothermia)\
                                                                                                                                                                                                                                                                                                                                                                          pH ≥ 7.2\
                                                                                                                                                                                                                                                                                                                                                                          ionised Ca ^++^ concentration \> 0.9 mmol/l (preferably normocalcaemia)

  2\.                                                                                                                                                                                                                                      Prevent potential (hyper-) fibrinolysis (always [PRIOR]{.ul} to the administration of fibrinogen and/or FFP!)                  Tranexamic acid (Cyklokapron ^®^ ) initially 1 -- 2 g (15 -- 30 mg/kg BW), repeat as needed

  3\.                                                                                                                                                                                                                                      Substitution of oxygen carriers                                                                                                RBC administration\
                                                                                                                                                                                                                                                                                                                                                                          Haemostatic target in patients with severe bleeding: Hb \~ 7 -- 9 g/dl (4.3 -- 5.5 mmol/l) or Hct \~ 30%

  4\.                                                                                                                                                                                                                                      Substitution of clotting factors (if severe haemorrhage persists) depending on availability in hospital                        FFP ≥ 20 (preferably 30) ml/kg BW\
                                                                                                                                                                                                                                                                                                                                                                          [or/and]{.ul}\
                                                                                                                                                                                                                                                                                                                                                                          fibrinogen (Haemocomplettan ^®^ ) (2--)4(--8) g (30 -- 60 mg/kg BW)\
                                                                                                                                                                                                                                                                                                                                                                          Target: ≥ 200 mg/dl or ≥ 2.0 g/l

  Patients who require (or are anticipated to require) massive transfusion or suffer life-threatening haemorrhagic shock may benefit from high FFP : RBC ratio of ≥1 : 2 or from combined administration of FFP and factor concentrates.   If required, PCC initially 1000 -- 2500 IU (25 IU/kg BW)                                                                       

  If required, 1 -- 2×FXIII (Fibrogammin ^®^ P) 1250 IU (15 -- 20 IU/kg BW)                                                                                                                                                                                                                                                                                               

  [and]{.ul} (if thrombocytopenia is suspected) increased platelet adhesion to endothelium + release of von Willebrand factor and FVIII from endothelium/liver sinusoids (→ agonist for vasopressin type 2 receptor)                       DDAVP = desmopressin (Minirin ^®^ )\                                                                                           
                                                                                                                                                                                                                                           0.3 µg/kg BW over a period of 30 minutes (1 vial per 10 kg BW over a period of 30 min)                                         

  5\.                                                                                                                                                                                                                                      Platelet substitution for primary haemostasis                                                                                  Platelet concentrate (target for haemorrhage requiring transfusion: 100 000/µl)

  6\.                                                                                                                                                                                                                                      If necessary, thrombin burst with platelet and coagulation activation (consider general haemostatic conditions!)               In individual cases and when all other treatment options have been unsuccessful\
                                                                                                                                                                                                                                                                                                                                                                          rFVIIa (NovoSeven ^®^ ) if required, initially 90 µg/kg BW

  During ongoing bleeding                                                                                                                                                                                                                  [No antithrombin (ATIII) during haemorrhage]{.ul} , may be considered after administration of PCC and cessation of bleeding\   
                                                                                                                                                                                                                                           [No heparin during haemorrhage]{.ul}                                                                                           

                                                                                                                                                                                                                                           CAUTION: Thrombosis prophylaxis is mandatory within 24 hours after cessation of the pathology causing the bleeding!            
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------

### 9.4  Rotational thromboelastometry (ROTEM)/thromboelastography (TEG)

The mean time until the results of standard laboratory parameters are available in the operating room is at least 45 minutes [@R5820122-139] . Coagulation disturbances can be detected significantly faster with the viscoelastic test (VET) [@R5820122-139] ,  [@R5820122-140] .

Currently, two procedures are used for point-of-care (POC) diagnostics offering prompt, bedside recognition of clotting disorders based on VET: rotational thromboelastometry (ROTEM, Tem International GmbH, Munich, Germany) and thromboelastography (TEG, Haemonetics, Braintree, MA, USA) [@R5820122-141] .

At present there are no class 1 recommendations on the use of these procedures [@R5820122-46] .

10  Transportation
------------------

  Consensus-based Recommendation 10.E35
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  As transporting a haemodynamically instable patient is a serious risk, any transportation of such patients as part of the management of PPH must be carefully weighed up, quite apart from the organisational conditions at the facility caring for the patient (or transportation should only be considered after haemodynamic stabilisation). It is important that the facility transferring the patient and the facility accepting the patient agree about timing and staff coverage during transportation of the patient in the run-up to the patient transfer and record what the two facilities have agreed upon in writing [@R5820122-142] .

11  Monitoring after PPH
------------------------

  Consensus-based Recommendation 11.E36
  --------------------------------------------------------------------------------------------------
  Following PPH, individually adapted active monitoring must be carried out for at least 24 hours.

12  Documentation
-----------------

  Consensus-based Recommendation 12.E37
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Every event defined as an emergency must be carefully documented. It is recommended to use the special forms developed for the respective organisational unit for documentation.

13  Debriefing
--------------

  Consensus-based Recommendation 13.E38
  ---------------------------------------------------
  Interdisciplinary team debriefing is recommended.

14  Training
------------

  Consensus-based Recommendation 14.E39
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Simulations of haemorrhagic situations must be carried out by an interdisciplinary team at regular intervals; studies have shown that this leads to an improvement in the management of peri-/postpartum haemorrhage [@R5820122-35] ,  [@R5820122-143] .
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Peripartale Blutungen, Diagnose und Therapie. Leitlinie der DGGG, OEGGG und SGGG (S2k-Level, AWMF-Registernummer 015/063, März 2016)

**Ziel** Erstellung einer offiziellen interdisziplinären Leitlinie, publiziert und koordiniert von der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe (DGGG), der Österreichischen Gesellschaft für Gynäkologie und Geburtshilfe (OEGGG) und der Schweizerischen Gesellschaft für Gynäkologie und Geburtshilfe (SGGG). Die Leitlinie wurde für den deutschsprachigen Raum entwickelt und wird von der Deutschen Gesellschaft für Anästhesiologie und Intensivmedizin (DGAI), der Gesellschaft für Thrombose- und Hämostaseforschung (GTH) und dem Deutschen Hebammenverband mitgetragen. Das Ziel dieser Leitlinie ist es, durch die Evaluation der relevanten Literatur einen konsensbasierten Überblick über die Diagnostik und das Management der peripartalen Blutung zu geben.

**Methoden** Diese S2k-Leitlinie wurde durch einen strukturierten Konsens von repräsentativen Mitgliedern verschiedener Fachgesellschaften und Professionen im Auftrag der Leitlinienkommission der DGGG entwickelt.

**Empfehlungen** Es werden Empfehlungen zur Definition, Risikostratifizierung, Prävention und Management gegeben.
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Leitliniendokumente
===================

Die vollständige Langversion mit einer Aufstellung der Interessenkonflikte aller Autoren und eine PDF-Dia-Version für PowerPoint-Präsentationen können auf der Homepage der AWMF eingesehen werden: <http://www.awmf.org/leitlinien/detail/ll/015-063.html>

Leitliniengruppe
================

Die folgenden Fachgesellschaften/Arbeitsgemeinschaften/Organisationen/Vereine haben Interesse an der Mitwirkung bei der Erstellung des Leitlinientextes und der Teilnahme an der Konsensuskonferenz bekundet und Vertreter für die Konsensuskonferenz benannt ( [Tab. 1](#TB5820122DE-1){ref-type="table"} ).

###### 
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A./Aa.

:   Arteria/Arteriae

AAGBI

:   The Association of Anaesthetists of Great Britain and Ireland

AMSTL

:   Active Management of Third Stage of Labor

aPTT

:   aktivierte partielle Thrombinzeit

AT/AT III

:   Antithrombin/Antithrombin III

b. B.

:   bei Bedarf

bds

:   beidseits

BGA

:   Blutgasanalyse

BMI

:   Body-Mass-Index

BV

:   Blutverlust

CMACE

:   Centre for Maternal and Child Enquiries

DDAVP

:   Desmopressin

DIG

:   disseminierte intravasale Gerinnung

EK

:   Erythrozytenkonzentrat

ESA

:   European Society of Anesthesiology

FWE

:   Fruchtwasserembolie

GFP

:   gefrorenes Frischplasma

Hb

:   Hämoglobin

HF

:   Herzfrequenz

Hkt

:   Hämatokrit

IE

:   internationale Einheit

i. m.

:   intramuskulär

INR

:   International normalized Ratio

IUFT

:   intrauteriner Fruchttod

i. v.

:   intravenös

MRT

:   Magnetresonanztomografie

NICE

:   National Institute for Health and Care Excellence

OAA

:   Obstetric Anaesthesists Association

OR

:   Odds Ratio

POC

:   Point of Care

PPH

:   postpartale Blutung/Postpartal Haemorrhage

PPSB

:   Prothrombinkomplexkonzentrat

rFVIIa

:   rekombinanter Faktor VIIa

ROTEM

:   Rotationsthrombelastometrie

RR ~sys~ /RR ~dia~

:   RR systolisch/RR diastolisch

TEG

:   Thrombelastografie

US

:   Ultraschall

V. a.

:   Verdacht auf

VET

:   viskoelastischer Test

Vv.

:   Venae

WHO

:   World Health Organisation

Z. n.

:   Zustand nach  

II  Leitlinienverwendung
========================

Fragestellung und Ziele
=======================

Intention dieser Leitlinie ist die Erstellung eines interdisziplinären (Anästhesie und Intensivmediziner, Geburtshelfer, Hebammen, Wochenbettpflege) Management- und Handlungsalgorithmus für das Management der peripartalen Blutungen (Diagnostik, Risikoselektion, Therapie).

Durch die Erstellung einer Leitlinie soll eine Verbesserung des Wissens aller bei der Betreuung von Schwangeren und Wöchnerinnen mit Hämorrhagie bzw. einem erhöhten Risiko für eine Hämorrhagie involvierten Personen und Berufsgruppen erreicht werden.

Somit sollen eine bessere Versorgung der Patientinnen erreicht werden sowie Probleme im Management der PPH reduziert werden.

Versorgungsbereich
==================

-   ambulanter Versorgungssektor

-   primärärztliche/spezialisierte Versorgung

-   stationärer Versorgungssektor

Anwenderzielgruppe/Adressaten
=============================

Diese Leitlinie richtet sich an folgende Personenkreise:

-   GynäkologInnen/GeburtshelferInnen in der Niederlassung

-   GynäkologInnen/GeburtshelferInnen mit Klinikanstellung

-   AnästhesistInnen und IntensivmedizinerInnen

-   GerinnungsspezialistInnen und LabormedizinerInnen

-   interventionelle RadiologInnen

-   Hebammen

-   Pflegekräfte (OP, Anästhesie, Intensivstation, Geburtshilfe/Wochenbett)

Verabschiedung und Gültigkeitsdauer
===================================

Die Gültigkeit dieser Leitlinie wurde durch die Vorstände/Verantwortlichen der beteiligten Fachgesellschaften/Arbeitsgemeinschaften/Organisationen/Vereine sowie durch den Vorstand der DGGG und der DGGG-Leitlinienkommission sowie der SGGG und OEGGG im September 2015 bestätigt und damit in ihrem gesamten Inhalt genehmigt. Diese Leitlinie besitzt eine Gültigkeitsdauer von 01.04.2016 bis 31.03.2019. Diese Dauer ist aufgrund der inhaltlichen Zusammenhänge geschätzt. Bei dringendem Bedarf kann eine Leitlinie früher aktualisiert werden, bei weiterhin aktuellem Wissensstand kann ebenso die Dauer verlängert werden.

III  Methodik
=============

Grundlagen
==========

Die Methodik zur Erstellung dieser Leitlinie wird durch die Vergabe der Stufenklassifikation vorgegeben. Das AWMF-Regelwerk (Version 1.0) gibt entsprechende Regelungen vor. Es wird zwischen der niedrigsten Stufe (S1), der mittleren Stufe (S2) und der höchsten Stufe (S3) unterschieden. Die niedrigste Klasse definiert sich durch eine Zusammenstellung von Handlungsempfehlungen, erstellt durch eine nicht repräsentative Expertengruppe. Im Jahr 2004 wurde die Stufe S2 in die systematische evidenzrecherchebasierte (S2e) oder strukturelle konsensbasierte Unterstufe (S2k) gegliedert. In der höchsten Stufe S3 vereinigen sich beide Verfahren.

Diese Leitlinie entspricht der Stufe: **S2k**

Empfehlungsgraduierung
======================

Die Evidenzgraduierung und Empfehlungsgraduierung einer Leitlinie auf S2k-Niveau ist nicht vorgesehen. Es werden die einzelnen Statements und Empfehlungen nur sprachlich -- nicht symbolisch -- unterschieden ( [Tab. 2](#TB5820122DE-2){ref-type="table"} ).

###### 

**Tab. 2**  Graduierung von Empfehlungen.

  Beschreibung der Verbindlichkeit                    Ausdruck
  --------------------------------------------------- ---------------------
  starke Empfehlung mit hoher Verbindlichkeit         soll/soll nicht
  einfache Empfehlung mit mittlerer Verbindlichkeit   sollte/sollte nicht
  offene Empfehlung mit geringer Verbindlichkeit      kann/kann nicht

Die oben aufgeführte Einteilung von **„Empfehlungen"** entspricht neben der Bewertung der Evidenz auch der klinischen Relevanz der zugrunde liegenden Studien und ihren nicht in der Graduierung der Evidenz aufgeführten Maßen/Faktoren, wie die Wahl des Patientenkollektivs, Intention-to-treat- oder Per-Protocol-Outcome-Analysen, ärztliches bzw. ethisches Handeln gegenüber dem Patienten, länderspezifische Anwendbarkeit usw.

Statements
==========

Sollten fachliche Aussagen nicht als Handlungsempfehlungen, sondern als einfache Darlegung Bestandteil dieser Leitlinie sein, werden diese als **„Statements"** bezeichnet. Bei diesen Statements ist die Angabe von Evidenzgraden [nicht]{.ul} möglich.

Konsensusfindung und Konsensusstärke
====================================

Im Rahmen einer strukturellen Konsensusfindung (S2k/S3-Niveau) stimmen die berechtigten Teilnehmer der Sitzung die ausformulierten Statements und Empfehlungen ab. Hierbei kann es zu signifikanten Änderungen von Formulierungen etc. kommen. Abschließend wird abhängig von der Anzahl der Teilnehmer eine Stärke des Konsensus ermittelt ( [Tab. 3](#TB5820122DE-3){ref-type="table"} ).

###### 

**Tab. 3**  Einteilung zur Zustimmung der Konsensusbildung.

  Symbolik   Konsensusstärke            prozentuale Übereinstimmung
  ---------- -------------------------- --------------------------------------------
  +++        starker Konsens            Zustimmung von \> 95% der Teilnehmer
  ++         Konsens                    Zustimmung von \> 75 -- 95% der Teilnehmer
  \+         mehrheitliche Zustimmung   Zustimmung von \> 50 -- 75% der Teilnehmer
  --         kein Konsens               Zustimmung von \< 50% der Teilnehmer

Expertenkonsens
===============

Wie der Name bereits ausdrückt, sind hier Konsensusentscheidungen speziell für Empfehlungen/Statements ohne vorige systemische Literaturrecherche (S2k) oder aufgrund von fehlender Evidenzen (S2e/S3) gemeint. Der zu benutzende Expertenkonsens (EK) ist gleichbedeutend mit den Begrifflichkeiten aus anderen Leitlinien wie „Good Clinical Practice" (GCP) oder „klinischer Konsensuspunkt" (KKP). Die Empfehlungsstärke graduiert sich gleichermaßen wie bereits im Kapitel Empfehlungsgraduierung beschrieben ohne die Benutzung der aufgezeigten Symbolik, sondern rein semantisch („soll"/„soll nicht" bzw. „sollte"/„sollte nicht" oder „kann"/„kann nicht").

IV  Leitlinie
=============

1  Hintergrund
==============

Die Inzidenz der postpartalen Hämorrhagie (PPH) steigt kontinuierlich [@R5820122-1] ,  [@R5820122-2] ,  [@R5820122-3] ,  [@R5820122-4] ,  [@R5820122-5] , vor allem bedingt durch die Zunahme von Uterusatonien und Plazentaimplantationsstörungen sowie steigenden Raten an vaginaloperativen und Kaiserschnittentbindungen mit konsekutiv erhöhten primären Blutverlusten sowie im Falle des Kaiserschnittes erhöhten PPH-Raten in Folgeschwangerschaften [@R5820122-2] ,  [@R5820122-6] ,  [@R5820122-7] ,  [@R5820122-8] ,  [@R5820122-9] ,  [@R5820122-10] ,  [@R5820122-11] .

Lebensbedrohliche postpartale Blutungen betreffen in der westlichen Welt ca. 2/1000 Geburten, hinzu kommt die schwere maternale Morbidität bei ca. 3/1000 Geburten [@R5820122-12]  --  [@R5820122-22] . Die PPH ist damit Ursache für ca. 30% aller maternalen Todesfälle in der Dritten Welt und 13% in industrialisierten Ländern [@R5820122-21] .

Der Großteil der maternalen Todesfälle aufgrund einer PPH ist vermeidbar, in 60 -- 80% aller Fälle liegt ein „major substandard care" vor [@R5820122-1] ,  [@R5820122-20] ,  [@R5820122-21] ,  [@R5820122-23] ,  [@R5820122-24] ,  [@R5820122-25] . Besonders bedrohlich ist, dass bei visueller Beurteilung das Ausmaß der Blutung um 30 -- 50% unterschätzt wird [@R5820122-26] ,  [@R5820122-27] ,  [@R5820122-28] ,  [@R5820122-29] .

Die Ursachen der PPH werden im angloamerikanischen Sprachgebrauch nach den „4 Tʼs" eingeteilt (Kombinationen dieser Ursachen sind die Regel) ( [Tab. 4](#TB5820122DE-4){ref-type="table"} ).

###### 

**Tab. 4**  Die 4 Tʼs: Ursachen der PPH [@R5820122-6] ,  [@R5820122-16] ,  [@R5820122-30] ,  [@R5820122-31] ,  [@R5820122-32] .

  -------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Tonus (uterine Atonie)     **uterine Überdehnung** (Multiparität, Hydramnion, fetale Makrosomie)\
                             Tokolytika\
                             schnelle oder verzögerte Geburt\
                             (lange) Oxytocinsubstitution\
                             Chorioamnionitis\
                             Uterus myomatosus

  Tissue (Plazenta)          Plazentaretention\
                             **Plazentaimplantationsstörung** (Placenta adhaerens, accreta/increta/percreta)\
                             Plazentaresiduen

  Trauma                     vulvovaginale Verletzungen\
                             Riss im Bereich der Cervix uteri\
                             Episiotomie/Dammriss\
                             Uterusruptur\
                             Uterusinversion

  Thrombin (Koagulopathie)   **schwangerschaftsinduziert:**\
                             Thrombozytopenie bei HELLP-Syndrom, disseminierte intravasale Gerinnung (DIG) (z. B. bei Präeklampsie, intrauteriner Fruchttod \[IUFT\], Abruptio placentae, Fruchtwasserembolie)\
                             **andere:**\
                             Von-Willebrand-Jürgens-Syndrom, plasmatische Gerinnungsstörungen, Thrombopathien, Faktorenmangel (Verlust, Verbrauch, Verdünnung)
  -------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Als Hauptprobleme im Risikomanagement der PPH werden angeführt [@R5820122-1] ,  [@R5820122-24] ,  [@R5820122-33] ,  [@R5820122-34] :

-   Verzögerung der Diagnose und/oder Therapie durch eine Unterschätzung des tatsächlichen Blutverlusts

-   Verzögerung in der Bereitstellung von Blut- respektive Gerinnungsprodukten

-   Fehlen oder Nichtbefolgen von einfachen Handlungsanweisungen

-   Fehlen von adäquater Fortbildung und Training

-   schlechte Kommunikation im interdisziplinären Team

-   Defizite in der Organisationsstruktur

-   Verzögerung bei der Initiierung eines Behandlungsstandards

2  Definitionen
===============

  Konsensbasierte Empfehlung 2.E1
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Folgende **Definition der PPH** wird (im deutschsprachigen Raum) empfohlen: Blutverlust von ≥ 500 ml nach vaginaler GeburtBlutverlust von ≥ 1000 ml nach Sectio caesarea

3  Risikostratifizierung und Prävention
=======================================

Eine exakte Anamnese, die Ultraschalldiagnostik in der Schwangerschaftsvorsorge, die Einschätzung eines Blutungsrisikos, die Vorstellung in der Geburtsklinik, die rechtzeitige Vorbereitung auf einen erhöhten Blutverlust können das Patientinnenrisiko für eine PPH reduzieren [@R5820122-35] .

  Konsensbasierte Empfehlung 3.E2
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Beim Ultraschall im II. Trimenon ist die Lokalisation und die Struktur der Plazenta zu dokumentieren. Bei tiefem Plazentasitz sollte das Vorhandensein von Vasa praevia ggf. im Rahmen einer weiterführenden Ultraschalluntersuchung überprüft und dokumentiert werden [@R5820122-36] .

  Konsensbasierte Empfehlung 3.E3
  -------------------------------------------------------------------------------------------------------------------------------------------------
  Besonders bei anamnestischen Risiken (Voroperationen) oder Befundrisiken (Placenta praevia) sollte an eine Implantationsstörung gedacht werden.

3.1  Risikostratifizierung und Risikofaktoren, die eine peri-/postpartale Blutung begünstigen ( [Tab. 5](#TB5820122DE-5){ref-type="table"} )
============================================================================================================================================

###### 

**Tab. 5**  Risikofaktoren bei PPH [@R5820122-16] ,  [@R5820122-23] ,  [@R5820122-37] ,  [@R5820122-38] ,  [@R5820122-39] .

                                          **OR oder Range**   
  --------------------------------------- ------------------- --------------
  Blutverlust                             \> 500 ml           \> 1000 ml
  soziodemografische Risikofaktoren                           
  Adipositas (BMI \> 35)                  1,6                 
  maternales Alter (≥ 30 Jahre)           1,3 -- 1,4          1,5
  geburtshilfliche Risikofaktoren                             
  Placenta praevia                        4 -- 13,1           15,9
  vorzeitige Plazentalösung               2,9 -- 12,6         2,6
  Plazentaretention                       4,1 -- 7,8          11,7 -- 16,0
  prolongierte Plazentarperiode           7,6                 
  Präeklampsie                            5,0                 
  Mehrlingsgravidität                     2,3 -- 4,5          2,6
  Z. n. PPH                               3,0 -- 3,6          
  fetale Makrosomie                       1,9 -- 2,4          
  HELLP-Syndrom                           1,9                 
  Hydramnion                              1,9                 
  (langanhaltende) Oxytocinaugmentation   1,8                 
  Geburtseinleitung                       1,3 -- 2            2,1 -- 2,4
  protrahierte Geburt                     1,1 -- 2            
  operative Risikofaktoren                                    
  Notkaiserschnitt                        3,6                 
  elektive Sectio caesarea                2,5                 
  vaginaloperative Entbindung             1,8 -- 1,9          
  Episiotomie                             1,7 -- 2,21         2.07
  Dammriss                                1,7                 2,5
  sonstige Risikofaktoren                                     
  antepartale Blutung                     3,8                 
  Von-Willebrand-Syndrom                  3,3                 
  Anämie (\< 9 g/dl)                      2,2                 
  Fieber unter der Geburt                 2                   

Als weitere Risikofaktoren sind eine rasche Geburt, hohe maternale Parität sowie Myome und Fehlbildungen des Uterus zu berücksichtigen [@R5820122-39] .

**[Cave:]{.ul}** Die Mehrzahl der Patientinnen, die eine PPH entwickeln, haben keine Risikofaktoren [@R5820122-39] .

3.2  Sonografische Risikostratifizierung (Plazentationsstörungen)
=================================================================

  Konsensbasierte Empfehlung 3.E4
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patientinnen mit V. a. Plazentationsstörung sollen grundsätzlich frühzeitig in einer geeigneten Geburtsklinik vorgestellt werden und dort von einem multidisziplinären Team („zum optimalen Zeitpunkt vom optimalen Team") behandelt werden [@R5820122-20] ,  [@R5820122-40] .

Der diagnostische Wert der MRT-Untersuchung ist in diesen Fällen bisher nicht überzeugend belegt [@R5820122-41] ,  [@R5820122-42] , jedoch kann bei unklaren Befunden die MRT-Untersuchung Zusatzinformationen liefern [@R5820122-42] ,  [@R5820122-43] .

3.3  Prävention
===============

4  Management bei PPH
=====================

  Konsensbasiertes Statement 4.S1
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Die Therapie einer PPH beinhaltet neben allgemeinen Maßnahmen (u. a. zur Kreislaufstabilisierung) die ursachenadaptierte medikamentöse und/oder chirurgische Therapie, die rasch, koordiniert und oft zeitgleich durchgeführt werden müssen [@R5820122-45] ,  [@R5820122-46] ,  [@R5820122-47] .

4.1  Maßnahmen
==============

-   Blutverlust messen! (Cave: Blutverluste in Tüchern usw.)

-   rasche Klärung der Blutungsursache („4 Tʼs"):

    -   Uterustonus tasten

    -   auf unvollständige Plazenta überprüfen (Ultraschallkontrolle, manuelles oder instrumentelles Austasten)

    -   Trauma der Geburtswege durch Spiegeleinstellung ausschließen

    -   bei kritischem Blutverlust Applikation von Uterotonika (bei Atonie) und Tranexamsäure

    -   Uteruskompression

-   frühzeitiges Hinzuziehen der Anästhesisten (multidisziplinäres Team)

-   ursachenabhängig medikamentöse und/oder chirurgische Therapie

-   Kontrolle der Vitalparameter, evtl. invasives Monitoring

-   initiale Volumensubstitution zum Erhalt der Normovolämie: Kristalloide, in Ausnahmefällen (z. B. akute Blutung mit Kreislaufinstabilität) kolloidale Lösungen [@R5820122-48]

-   Blut kreuzen lassen, Notfalllabor (u. a. Blutbild, Gerinnung)

-   Erythrozytenkonzentrate und Gefrierplasma bestellen, ggf. bereitstellen (Kreißsaal, OP)

-   Gerinnungsfaktoren, vor allem Fibrinogen

-   andere Hämostatika (z. B. Desmopressin), Faktor XIII und ggf. rFVIIa

-   Intensivüberwachung im stationären Verlauf, evtl. invasives Monitoring

-   rechtzeitige operative Intervention bei Versagen konservativer Maßnahmen (Vorgehen siehe unten)

5  Allgemeine (Notfall-)Maßnahmen und Diagnostik zur Ursachenklärung
====================================================================

5.1  Atonie
===========

-   [Diagnose:]{.ul} Anstieg des Fundus uteri; weicher, schlaffer Uterus; meist intermittierende, schwallartige Blutung.

-   Blase entleeren!

-   mechanische Maßnahmen: Massage des Uterus (endogene Prostaglandinbildung), bimanuelle Uteruskompression (z. B. Handgriff nach Hamilton)

-   Ausschluss von Geburtsverletzungen (Spiegeleinstellung und ggf. abdominaler US)

-   Ausschluss von Plazentaresten (Kontrolle der Plazenta auf Vollständigkeit, Sonografie)

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Konsensbasierte Empfehlung 5.E10
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Therapie:**\
  nach vaginaler Entbindung\
  Uterotonika, ggf. Tranexamsäurebei V. a. Plazentaresiduen schonende Kürettage im Kreißsaal oder im OPggf. Uterustamponadeweitere chirurgische Maßnahmenevtl. Embolisationnach Sectio caesareaUterotonika, ggf. Tranexamsäurechirurgische Maßnahmen

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

5.2  Implantationsstörungen
===========================

Das Management einer Plazentalösungsstörung ist abhängig vom Zeitpunkt der Diagnosestellung und dem Geburtsmodus.

5.3  Inversio uteri
===================

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Konsensbasierte Empfehlung 5.E12
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Therapie:**\
  Ziel ist die Reposition des Uterus sowie die Behandlung der blutungsbedingten Schocksymptomatik; die folgenden Maßnahmen sollen sofort nach Diagnosestellung in dieser Reihenfolge durchgeführt werden:Beendigung der UterotonikagabeZuziehen geburtshilflicher Facharzt und AnästhesieSchaffung adäquater, intravenöser Zugänge, Volumensubstitutionkein Versuch einer Plazentaentfernung, diese soll wegen des erhöhten Blutverlusts falls möglich (Placenta accreta) erst nach Reposition entfernt werden [@R5820122-53] ,  [@R5820122-54]Versuch einer Repositionierung des Fundus (Johnson-Manöver)falls frustran, Gabe von Uterusrelaxanzien (z. B. Nitroglyzerin 50 µg i. v., Betamimetika) und neuerlicher Repositionsversuch mittels Johnson-Manöverfalls weiter frustran → Laparotomie und Huntington-Manöver, ggf. simultan Johnson-Manöver; falls frustran, Durchführung des Haultain-Manöversnach Reposition Uterotonikagabe (z. B. Oxytocin)antibiotische Abschirmung (z. B. Cephalosporin oder Clindamycin)

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

6  Medikamentöse und operative Maßnahmen zur Behandlung der PPH
===============================================================

6.1  Uterotonika
================

7  Uterustamponade
==================

Der Einsatz der Cavumtamponade wird mit 2 Zielsetzungen durchgeführt: einerseits der Therapie der PPH, d. h. dem definitiven Blutungsstopp, und andererseits dem Ziel des „bridging", d. h. einem temporären Blutungsstopp, um eine hämodynamische Stabilisierung oder die Organisation von weiteren (operativen oder interventionell-radiologischen) Maßnahmen zu ermöglichen [@R5820122-62] ,  [@R5820122-63] ,  [@R5820122-64] . Neben anderen sogenannten „second-line" Therapiestrategien kann die Tamponade des Uterus die Rate von Notfallhysterektomien signifikant reduzieren [@R5820122-65] ,  [@R5820122-66] .

Zur Tamponade des Uterus stehen neben Tamponadestreifen verschiedene Ballonsysteme zur Verfügung, deren Effektivität in verschiedenen Publikationen nachgewiesen wurde und die den Vorteil einer frühzeitigen Erkennung einer persistierenden Blutung bieten [@R5820122-64] ,  [@R5820122-67] ,  [@R5820122-68] ,  [@R5820122-69] ,  [@R5820122-70] ,  [@R5820122-71] ,  [@R5820122-72] ,  [@R5820122-73] .

  Konsensbasierte Empfehlung 7.E18
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Uterotonikamedikation parallelvaginale Untersuchung/Ultraschall (Ausschluss Trauma, Plazentarest, Koagelentleerung)Blasenkatheterzum Füllen des Tamponadeballons Flüssigkeit (0,9% NaCL, möglichst körperwarm) -- KEINE Luftzusätzlich vaginale TamponadeIntensivüberwachung (Monitoring), Antibiotikaprophylaxekann bis zu 24 Stunden in utero belassen werden

Die erfolgreiche Anwendung einer mit einer hämostatischen Komponente (Chitosan) beschichteten und für die Notfall- bzw. Kriegsmedizin entwickelten Gaze (Celox ^®^ ) im Management der PPH wurde kürzlich berichtet [@R5820122-74] .

  Konsensbasierte Empfehlung 7.E19
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Die Tamponade des Uterus -- in welcher Form auch immer -- schließt andere evtl. notwendige weitere therapeutische Optionen, wie z. B. Kompressionsnähte, nicht aus [@R5820122-64] ,  [@R5820122-75] , diese sind gerade bei Atonie dringend zu empfehlen [@R5820122-75] ,  [@R5820122-76] ,  [@R5820122-77] ,  [@R5820122-78] .

8  Operative Maßnahmen (Kompression, Devaskularisation, Hysterektomie) und Embolisation
=======================================================================================

8.1  Überbrückende Maßnahmen
============================

  Konsensbasierte Empfehlung 8.E20
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  In der Situation der letalen Trias „anhaltende Blutung, hämorrhagischer Schock und Koagulopathie" empfiehlt sich ein Vorgehen in 3 Phasen [@R5820122-62] : Chirurgische Blutstillung in einer akzeptablen Zeitspanne auch mit chirurgisch-geburtshilflicher „Basisexpertise" per Pfannenstiel- oder medianer Laparotomie, Eventeration des Uterus mit Zug nach kranial und Uteruskompression sowie Setzen von atraumatischen Klemmen im Bereich der Aa. uterinae, um die Perfusion zu minimieren. Setzen von Uteruskompressionsnähten und Applikation einer Uterustamponade.Parallel Korrektur von Hypovolämie, Temperatur, Säure-Basen-Haushalt und Koagulopathie durch anästhesiologisch-intensivmedizinische Maßnahmen; ggf. folgende Operationspause zur Stabilisierung.Definitive (chirurgische) Versorgung der jetzt stabilen Patientin durch einen Operateur mit entsprechender chirurgischer Expertise. Bei vorhandener Infrastruktur kann hier optional auch eine interventionell radiologische Embolisation der zuführenden uterinen Arterien vorgenommen werden [@R5820122-79] ,  [@R5820122-80] . Vorteil dieses Vorgehens könnte sein, dass die Fertilität erhalten bleiben kann, wie größere Fallserien beschrieben haben [@R5820122-81] ,  [@R5820122-82] ,  [@R5820122-83] ,  [@R5820122-84] .

8.2  Uteruskompressionsnähte
============================

Ziel dieser Nähte ist die Kompression des Uterus mit Verkleinerung der Plazentahaftfläche und die Tamponade der Blutungsquellen. Indiziert ist diese Maßnahme bei uterinen Blutungen nach vaginaler Geburt sowie nach vorausgegangener Sectio caesarea. Derzeit kann keine Aussage in Bezug auf die optimale Wirksamkeit einer Nahtmethode getroffen werden. Insgesamt zeigt sich eine hohe Erfolgsrate aller Methoden in Bezug auf eine Vermeidung der bisher üblichen Hysterektomie. Es sollten jedoch je nach Indikation (Atonie, Blutung aus dem Plazentabett, diffuse Blutung) eine geeignete Nahttechnik zum Einsatz kommen [@R5820122-85] .

  Konsensbasierte Empfehlung 8.E21
  ---------------------------------------------------------------------------------------------------------
  Entsprechendes Nahtmaterial (große Nadel, langer Faden) muss in den Operationssälen vorgehalten werden.

8.3  Gefäßligaturen
===================

Neben der einfachen Ligatur der A. uterina [@R5820122-86] kann auch die schrittweise uterine Devaskularisation eingesetzt werden. Diese Technik umfasst in 5 konsekutiven Schritten die Ligatur der auf- und absteigenden Äste der Aa. uterinae sowie der Kollateralen der A. ovarica [@R5820122-87] ,  [@R5820122-88] .

  Konsensbasierte Empfehlung 8.E22
  ---------------------------------------------------------------------------------------------------------------------------------------
  Die Ligatur der A. iliaca interna soll nur als Ultima Ratio und nur durch einen in der Beckenchirurgie erfahrenen Operateur erfolgen.

8.4  Postpartale Hysterektomie
==============================

  Konsensbasierte Empfehlung 8.E23
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Konservative Maßnahmen, um den Uterus zu erhalten, sind nur so lange sinnvoll, wie die Frau hämodynamisch stabil ist und nicht lebensbedrohlich blutet [@R5820122-89] ,  [@R5820122-90] . Eine notwendige Hysterektomie sollte daher nicht zu spät indiziert werden.

  Konsensbasierte Empfehlung 8.E24
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Bei Atonie ist die suprazervikale Hysterektomie zu bevorzugen, da die Operationszeit deutlich kürzer ist und es nicht zu einer ungewollten Verkürzung der Scheide kommt. Bei Plazentaimplantationsstörungen im unteren Uterinsegment ist die totale Hysterektomie zu erwägen, hier ist die Darstellung der Ureteren anzuraten.

8.5  Arterielle Katheterembolisation
====================================

  Konsensbasierte Empfehlung 8.E26
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Jede geburtshilfliche Abteilung sollte interdisziplinär abklären, ob und innerhalb welcher Zeit diese Methode im Klinikum zur Verfügung steht und dann entsprechende Organisationsstrukturen festlegen, zu welchem Zeitpunkt die Patientin in die interventionelle Radiologie verlegt wird. Voraussetzung ist eine hämodynamische stabile Patientin ohne massive Blutung.

  Konsensbasierte Empfehlung 8.E27
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Falls die Möglichkeit zur Katheterembolisation besteht, sollten die Radiologen frühzeitig (z. B. bei erfolgloser Blutstillung nach Uteruskompressionsnaht) verständigt werden. Aufgrund des Nebenwirkungsspektrums sollten die medikamentösen und operativen Therapieoptionen jedoch weitestgehend ausgeschöpft sein. Der Zeitpunkt der Verlegung wird auch dadurch definiert, wie relevant ein Organerhalt des Uterus ist.

  Konsensbasierte Empfehlung 8.E28
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Vor Verlegung sollte im Falle einer vorausgegangenen Hysterektomie ein intraabdominelles Packing als Bridging-Maßnahme erwogen werden, um kritische Blutverluste während des Transportes oder während der z. T. langwierigen Intervention einzudämmen.

  Konsensbasierte Empfehlung 8.E29
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Bei planbaren Eingriffen (z. B. Placenta increta/percreta) kann die Einlage von endovaskulären Kathetern in die A. iliaca interna bds. bereits präoperativ erfolgen.

Die Katheterembolisation kann evtl. auch als Ultima Ratio bei persistierender diffuser Blutung im kleinen Becken nach bereits erfolgter postpartaler Hysterektomie durchgeführt werden [@R5820122-93] .

9  Hämostase und Gerinnungsmanagement -- Intensivmedizinische Maßnahmen
=======================================================================

9.1  Hintergrund
================

Das Wissen um die wahrscheinlichste Pathophysiologie der Blutung ist wichtig, da sich hieraus Hinweise für unterschiedliche therapeutische Ansätze ableiten lassen. Die Schwierigkeit im hämostaseologischen Management liegt in der Problematik der Unterscheidung zwischen vermehrter Blutung aufgrund einer größeren Verletzung und einer protrahierten Blutung bei gleichzeitig veränderter Zusammensetzung des Blutes (sodass die normalerweise bestehende Kompensationsfähigkeit des Systems für kleinere Verletzungen aufgehoben ist, Störung des „Organsystems Gerinnung = Koagulopathie"). Unterschieden werden müssen somit:

-   die traumainduzierte Koagulopathie mit Schock und massiver Gewebeschädigung

-   die initial „traumatische" Blutung aufgrund einer Gewebeschädigung und

-   die initial koagulopathische Blutung.

Eine gestörte Gerinnbarkeit (= Koagulopathie) ist häufig eine frühe Pathologie bei PPH, die vor einer dilutionsbedingten Störung auftreten kann [@R5820122-39] ,  [@R5820122-94] .

  Konsensbasierte Empfehlung 9.E30
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Da die Resultate diagnostischer Maßnahmen zur Unterscheidung zwischen den verschiedenen Koagulopathien (z. B. kongenital vs. erworben) vor einer Behandlungsentscheidung aufgrund der resultierenden zeitlichen Verzögerung nicht abgewartet werden können, sollte im Regelfall (wenn anamnestisch keine kongenitale Koagulopathie bekannt ist) von einer peri- bzw. postpartalen Blutung mit erworbener Koagulopathie ausgegangen werden, es sei denn dass eindeutig eine chirurgische Ursache der Blutung identifiziert werden kann.

Wichtig ist dabei auch, die Erkenntnis zu berücksichtigen, dass jede primär mechanische Blutung, die mittels Volumenunterstützung und gefrorenem Frischplasma (GFP) behandelt wird, aufgrund des damit verbundenen Verdünnungseffektes und durch den Verbrauch von Gerinnungsfaktoren bei genügend langer Dauer auch zu einer koagulopathischen Blutung wird [@R5820122-95] ,  [@R5820122-96] ,  [@R5820122-97] .

  Konsensbasiertes Statement 9.S6
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Für alle Kliniken mit geburtshilflichen Abteilungen ist es daher unabdingbar, einen auf die jeweiligen Bedingungen der Klinik abgestimmten Behandlungsalgorithmus für die peri-/postpartale Blutung zu entwickeln [@R5820122-46] ,  [@R5820122-98] ,  [@R5820122-99] ,  [@R5820122-100] ,  [@R5820122-101] , der die frühzeitige Identifizierung blutender Patientinnen und die integrative chirurgische, interventionelle und hämostaseologische Behandlung der Blutung zum Ziel hat. Dieser Algorithmus sollte das Vorgehen während des Behandlungsprozesses auf der Grundlage der klinischen Situation definieren und alle verfügbaren Behandlungsmöglichkeiten (pharmakologische Therapien, interventionelle Maßnahmen, chirurgische Eingriffe) berücksichtigen.

9.2  Optionen zur Behandlung peri-/postpartaler koagulopathischer Blutungen
===========================================================================

  Konsensbasiertes Statement 9.S7
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Grundsätzlich sollte bei aktiven Blutungen, wenn möglich, eine iatrogene Aggravation der Blutungsneigung z. B. durch die Gabe künstlicher kolloidaler Volumenersatzlösungen, die einen stärkeren, dilutionsbedingten koagulopathischen Effekt oder die Erzielung eines hochnormalen Blutdrucks haben, vermieden werden.

  Konsensbasiertes Statement 9.S8
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Die hämostaseologische Standardtherapie ist heutzutage die Komponenten-Therapie, sei es durch den Einsatz labiler (zelluläre Komponenten, GFP) oder stabiler (lyophilisierte Faktorkonzentrate) Blutprodukte, die frühzeitig zum Einsatz kommen sollten, um eine zusätzlich zum Verlust auftretende Verdünnungskoagulopathie zu vermeiden.

Hierbei kommt nach gegenwärtigem Wissensstand dem **Fibrinogen** eine wichtige Rolle zu, sodass bei anamnestisch bekannten peri-/postpartalen Blutungen und bei peripartal blutenden Patientinnen die Fibrinogenkonzentration (unabhängig von der Therapie) bestimmt werden sollte, da Konzentrationen \< 2 g/l diejenigen Patientinnen identifizieren können, die ein erhöhtes Risiko für eine schwere PPH haben [@R5820122-39] ,  [@R5820122-46] .

  Konsensbasierte Empfehlung 9.E31
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Vor der Gabe von Fibrinogen (Faktorenkonzentrat oder GFP) sollte allerdings in jedem Fall eine möglicherweise parallel bestehende erhöhte fibrinolytische Aktivität durch die Gabe von **Tranexamsäure** (Antifibrinolytikum) behandelt werden [@R5820122-39] .

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Konsensbasiertes Statement 9.S9
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Vorteilhafte Effekte (reduzierter Blutverlust, reduzierte Transfusionsmenge, erhöhter Hb, geringere Anzahl an invasiven Maßnahmen) durch Anwendung von Tranexamsäure bei PPH wurden mittlerweile an rund 2000 Patientinnen in randomisiert, kontrollierten Studien nachgewiesen [@R5820122-102] ,  [@R5820122-103] ,  [@R5820122-104] ,  [@R5820122-105] ,  [@R5820122-106] ,  [@R5820122-107] ,  [@R5820122-108] ,  [@R5820122-109] ,  [@R5820122-110] .\
  Die ESA spricht 2013 eine starke Empfehlung bei moderater Evidenz für die Anwendung von Tranexamsäure bei geburtshilflichen Blutungen aus, um den Blutverlust, die Blutungsdauer und die Anzahl der Transfusionen zu senken [@R5820122-46] .\
  Zur Verwendung von **DDAVP** (Minirin ^®^ ) in der Geburtshilfe gibt es keine zuverlässige Datenbasis, die eine evidenzbasierte Empfehlung erlauben würde [@R5820122-111] , obgleich wiederholt Beobachtungen mit positivem Outcome berichtet wurden [@R5820122-112] . Gemäß ESA kann die Anwendung von DDAVP bei einer Thrombozytenfunktionsstörung infolge eines erworbenen Von-Willebrand-Syndroms (durch Medikamente, Azidose, Hypothermie) sinnvoll sein [@R5820122-46] .

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Konsensbasierte Empfehlung 9.E32
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Trotz der kontroversen Datenlage und obwohl prospektiv randomisierte Studien fehlen, kann ein 1- bis 2-maliger Behandlungsversuch mit rFVIIa als Ultima Ratio mit 90 µg/kgKG bei strenger Indikation unternommen werden, wenn die Patientinnen\
  mit anderen Blutprodukten adäquat vorbehandelt worden sind,bei denen andere Methoden zur Blutstillung ungenügend wirksam waren undihre Familienplanung noch nicht abgeschlossen haben, bevor eine Hysterektomie durchgeführt wird [@R5820122-39] ,  [@R5820122-113] ,  [@R5820122-114] ,  [@R5820122-115] ,  [@R5820122-116] . Rekombinanter FVIIa (NovoSeven ^®^ ) sollte aufgrund des thrombembolischen Risikos nur als „Ultima Ratio" gegeben werden [@R5820122-117] . Vor Gabe von rFVIIa sollten die plasmatischen Faktorkonzentrationen und die Thrombozytenzahl optimiert werden [@R5820122-46] .

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

  Konsensbasiertes Statement 9.S10
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Zusammengefasst lassen die heute verfügbaren Daten zum hämostaseologischen Management den Schluss zu, dassein eskalierendes, d. h. aus schrittweise aufeinander folgenden Therapieoptionen bestehendes Behandlungskonzept an die jeweiligen Gegebenheiten eines jeden Krankenhauses angepasst werden soll [@R5820122-46] ,  [@R5820122-99] ,  [@R5820122-100] ,die Gabe von Tranexamsäure früh, am besten unmittelbar nach Diagnosestellung erfolgen soll,eine Stabilisierung der „Rahmenbedingungen der Gerinnung" erfolgen soll, d. h. pH-Wert, Temperatur, Kalzium [@R5820122-46] ,  [@R5820122-95] ,mindestens bei fortbestehender Blutung die Diagnostik mittels viskoelastischer Verfahren oder konventioneller Gerinnungsdiagnostik angestrebt werden sollte,bei substitutionspflichtiger Blutung (und allenfalls parallel zu anderen mechanischen Therapieformen) der Ersatz von Gerinnungsfaktoren mittels Faktorkonzentraten und/oder GFP frühzeitig erfolgen soll (insbesondere bei Vorliegen einer Verdünnungskoagulopathie den Einsatz von Fibrinogen in Betracht ziehen, im Übrigen auch von PPSB und F XIII),bei Bedarf (d. h., wenn andere Maßnahmen nicht greifen) eine Optimierung der Thrombozytenzahl (Ziel bei transfusionspflichtigen Blutungen \> 100 000/µl in Betracht zu ziehen ist [@R5820122-46] .

  Konsensbasierte Empfehlung 9.E33
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nach Ende der zur Blutung führenden Pathologie ist innerhalb von 24 Stunden eine Thromboseprophylaxe erforderlich [@R5820122-39] . Aufgrund einer reduzierten Antithrombinaktivität (teilweise mit einer absoluten Aktivität unter 0,5 kIU/l) bei einer großen Anzahl von Frauen mit PPH ist **nach Ende der Blutung** mit einer erhöhten Gefährdung durch Thrombembolien zu rechnen [@R5820122-118] . Insbesondere nach Gabe von Gerinnungsfaktoreneinzelkonzentraten oder Komplexpräparaten (z. B. PPSB) kann dann auf der Intensivstation die Aktivität von Antithrombin bestimmt und ggf. substituiert werden [@R5820122-119] . Ein möglicher Zielwert liegt bei ≥ 80% bzw. ≥ 0,8 kIU/l [@R5820122-119] ,  [@R5820122-120] ,  [@R5820122-121] .

9.3  Anästhesierelevante Punkte beim Management der PPH
=======================================================

  Konsensbasierte Empfehlung 9.E34
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Hämodynamische Stabilität und Normovolämie erhalten oder erreichen: Eine **myokardiale Ischämie** mit reduzierter Kontraktilität findet sich häufig bei Hb-Werten ≤ 6 g/dl (3,726 mmol/l) mit oder auch ohne hämodynamische Auffälligkeiten (RR ~sys~  \< 90 mmHg und/oder RR ~dia~  \< 50 mmHg und/oder HF ≥ 115/min) [@R5820122-122] ,  [@R5820122-123] .**Zeitgerechter Ruf nach kompetenter Hilfe:** Bei nicht beherrschtem Blutverlust bei vaginaler Entbindung deutlich über 500 ml bzw. bei Sectio caesarea deutlich über 1000 ml empfohlen und ab einem Blutverlust von 1500 ml unabdingbar [@R5820122-29] ,  [@R5820122-89] ,  [@R5820122-95] ,  [@R5820122-124] .Bei **Regionalanästhesieverfahren** (Spinalanästhesie, Periduralanästhesie): Bei einem Blutverlust ≥ 1500 -- 2000 ml und anhaltenden Blutungszeichen: **Sicherung der Atemwege bzw. des O ~2~ -Angebotes** , ggf. in Rücksprache mit dem Operateur frühzeitige Intubation [@R5820122-125] . Bei bedrohten Schutzreflexen hat die endotracheale Intubation zur Atemwegssicherung und Sicherstellung der Sauerstoffversorgung Priorität.**Großlumige** Zugänge (2 × ≥ 16 G), im Anschluss die arterielle Blutdruckmessung, ggf. auch vor der Intubation. Großzügige Indikationsstellung für großlumigen zentralen Zugang (≥ 9 Fr) [@R5820122-125] ,  [@R5820122-126] ,  [@R5820122-127] ,  [@R5820122-128] .**Cell-Saver** (offizielle Empfehlungen von CMACE, NICE, OAA/AAGBI, ESA): Die Anwendung der maschinellen Autotransfusion bei einer elektiver Sectio caesarea (z. B. bei Placenta increta/percreta) kann die postoperative Fremdblutgabe und den Krankenhausaufenthalt reduzieren [@R5820122-129] ,  [@R5820122-130] . Im Notfall der PPH sind folgende **[Caves]{.ul}** zu beachten: Einsatz ggf. erst nach Fruchtwasserabsaugung und Kindsentwicklung.Cell-Saver-Blut enthält keine Gerinnungsfaktoren oder Thrombozyten. Zur Vermeidung einer Koagulopathie bei hohen Transfusionsvolumina sollten Gerinnungsfaktoren substituiert werden [@R5820122-131] .Es wurden Hypotonien bei der Re-Transfusion von Cell-Saver-Blut unter Verwendung eines Leukozytenfilters beobachtet [@R5820122-132] .**Zielwerte der hämodynamischen Therapie** bei „gesunden" Schwangeren und starker Blutung:**Nach Abnabelung „permissive Hypotension"** bis zur chirurgischen Blutstillung durch **restriktive Volumengabe** [@R5820122-133] ,  [@R5820122-134] .„Normale Rekapillarisierungszeit" oder „tastbarer Radialispuls" als Zielgröße für Volumentherapie [@R5820122-135] ,  [@R5820122-136]**Ziel:** MAP \> 65 mmHg, ggf. niedriger [@R5820122-137] bzw. RR ~sys~  \~ 90 mmHg [@R5820122-138] .**Ziel-Hb:** Indikation zu Bluttransfusionen bis zur chirurgischen Blutstillung **7 g/dl** (4,347 mmol/l), nach chirurgischer Blutstillung und Beendigung der Pathologie **7 -- 9 g/dl** (4,347 -- 5,589 mmol/l) [@R5820122-23] ,  [@R5820122-134] ,  [@R5820122-138] . Anmerkung: auf Station zusätzlich ausreichende Eisensubstitution.**Pharmakologische Thromboseprophylaxe** spätestens 24 h, nachdem die zur Blutung führende Pathologie beendet ist [@R5820122-134] .

###### 

Eskalierendes Schema der hämostaseologischen, therapeutischen Optionen der PPH (nach Empfehlungen aus der S3-Leitlinie 012/019 „Polytrauma/Schwerverletztenbehandlung", der DGAI-Empfehlung zur Massivblutung und der ESA-Empfehlungen zur perioperativen Blutung) [@R5820122-100] ,  [@R5820122-136] .

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------
  1\.                                                                                                                                                                                                                                                              Stabilisierung der Rahmenbedingungen (Prophylaxe und Therapie!)                                                                  Kerntemperatur ≥ 34 °C (möglichst Normothermie)\
                                                                                                                                                                                                                                                                                                                                                                                                    pH-Wert ≥ 7,2\
                                                                                                                                                                                                                                                                                                                                                                                                    ionisierte Ca ^++^ -Konzentration \> 0,9 mmol/l (möglichst Normokalzämie)

  2\.                                                                                                                                                                                                                                                              Hemmung einer potenziellen (Hyper-)Fibrinolyse (mmer [VOR]{.ul} Gabe von Fibrinogen und/oder GFP!)                               Tranexamsäure (Cyklokapron ^®^ ) initial 1 -- 2 g (15 -- 30 mg/kgKG), b. B. Wiederholung

  3\.                                                                                                                                                                                                                                                              Substitution von Sauerstoffträgern                                                                                               EK-Gabe\
                                                                                                                                                                                                                                                                                                                                                                                                    hämostaseologisches Ziel bei massiver Blutung: Hb \~ 7 -- 9 g/dl (4,3 -- 5,5 mmol/l) bzw. Hkt \~ 30%

  4\.                                                                                                                                                                                                                                                              Substitution von Gerinnungsfaktoren (bei fortbestehender schwerer Blutungsneigung) und je nach Vorhaltung im Krankenhaus         GFP ≥ 20 (eher 30) ml/kgKG\
                                                                                                                                                                                                                                                                                                                                                                                                    [oder/und]{.ul}\
                                                                                                                                                                                                                                                                                                                                                                                                    Fibrinogen (Haemocomplettan ^®^ ) (2--)4(--8) g (30 -- 60 mg/kgKG)\
                                                                                                                                                                                                                                                                                                                                                                                                    Ziel: ≥ 200 mg/dl bzw ≥ 2,0 g/l

  Patienten, die Massivtransfusionen benötigen (werden) oder einen blutungsbedingten, lebensbedrohlichen Schock haben, können von einem hohen Verhältnis GFP : EK im Bereich von ≥1 : 2 oder der kombinierten Gabe von GFP und Faktorenkonzentraten profitieren.   ggf. PPSB initial 1000 -- 2500 IE (25 IE/kgKG)                                                                                   

  ggf.  1 -- 2 × FXIII (Fibrogammin ^®^ P)1250 IE (15 -- 20 IE/kgKG)                                                                                                                                                                                                                                                                                                                                

  [und]{.ul} (bei V. a. Thrombozytopathie) verstärkte Thrombozytenadhäsion an das Endothel + Freisetzung von „Von-Willebrand-Faktor" und FVIII aus Endothel/Lebersinusoiden (→ Agonist für Vasopressinrezeptor Typ 2)                                              DDAVP = Desmopressin (Minirin ^®^ )\                                                                                             
                                                                                                                                                                                                                                                                   0,3 µg/kgKG über 30 Minuten („1 Ampulle pro 10 kgKG über 30 min")                                                                

  5\.                                                                                                                                                                                                                                                              Substitution von Thrombozyten für die primäre Hämostase                                                                          Thrombozytenkonzentrate (Ziel bei transfusionspflichtigen Blutungen: 100 000/µl)

  6\.                                                                                                                                                                                                                                                              ggf. „Thrombinburst" mit Thrombozyten- und Gerinnungsaktivierung („Rahmenbedingungen" der Hämostase beachten!)                   im Einzelfall und bei Erfolglosigkeit aller anderen Therapieoptionen\
                                                                                                                                                                                                                                                                                                                                                                                                    ggf. rFVIIa (NovoSeven ^®^ ) initial 90 µg/kgKG

  bei aktiver Blutung                                                                                                                                                                                                                                              [während Blutung kein]{.ul} Antithrombin (ATIII), ggf. nach PPSB-Gabe und Blutungsende erwägen\                                  
                                                                                                                                                                                                                                                                   [während Blutung kein]{.ul} Heparin                                                                                              

                                                                                                                                                                                                                                                                   **Cave** : Innerhalb von 24 Stunden nach Beendigung der zur Blutung führenden Pathologie ist eine Thromboseprophylaxe obligat!   
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------

9.4  Rotationsthrombelastometrie (ROTEM)/ Thrombelastografie (TEG)
==================================================================

Die durchschnittliche Dauer bis zur Vorlage des Ergebnisses im OP liegt für die Standardlaborparameter bei mindestens 45 Minuten [@R5820122-139] . Mit den sog. „viskoelastischen Tests (VET)" lässt sich eine Störung der Gerinnung deutlich schneller feststellen [@R5820122-139] ,  [@R5820122-140] .

Derzeit stehen für die sog. „point of care (POC)"-Diagnostik, also die zeit- und patientennahe, bettseitige Erkennung von Gerinnungsstörungen, mittels VET 2 Methoden zur Verfügung: die Rotationsthromboelastometrie (ROTEM, Tem International GmbH, München) und die Thrombelastografie (TEG, Haemonetics, Braintree, MA, USA) [@R5820122-141] .

Für den Einsatz dieser Verfahren bei der PPH liegen derzeit keine Klasse-1-Empfehlungen vor [@R5820122-46] .

10  Transport
=============

  Konsensbasierte Empfehlung 10.E35
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Da der Transport einer kreislaufinstabilen Patientin ein großes Risiko darstellt, gilt es -- abhängig von den organisatorischen Voraussetzungen der betreuenden Einheit -- im Verlauf des Managements einer PPH den Transfer der kreislaufinstabilen Patientin zu überdenken (bzw. einen Transport erst nach Kreislaufstabilisierung in Erwägung zu ziehen). Hier gilt es, bereits im Vorfeld Vereinbarungen über den zeitlichen Ablauf und die personelle Absicherung des Transportes zwischen Zielkrankenhaus und transferierendem Krankenhaus zu treffen und schriftlich festzuhalten [@R5820122-142] .

11  Überwachung nach PPH
========================

  Konsensbasierte Empfehlung 11.E36
  ----------------------------------------------------------------------------------------------------------------------------------
  Nach einer PPH soll eine individuell dem Einzelfall angepasste adäquate Überwachung (mindestens 24 Stunden) durchgeführt werden.

12  Dokumentation
=================

  Konsensbasierte Empfehlung 12.E37
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Für jedes definierte Notfallereignis ist eine sorgfältige Dokumentation essenziell. Es empfiehlt sich, hierfür an die Organisationseinheit angepasste Formulare zu benutzen.

13  Nachbesprechung
===================

  Konsensbasierte Empfehlung 13.E38
  ---------------------------------------------------------------------------------
  Eine interdisziplinäre Nachbesprechung im Team ist empfehlenswert (Debriefing).

14  Training
============

  Konsensbasierte Empfehlung 14.E39
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Simulation von Blutungssituationen im interdisziplinären Team soll in regelmäßigen Abständen durchgeführt werden und hat in Studien eine Verbesserung des Managements bewiesen [@R5820122-35] ,  [@R5820122-143] .
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